Current neoadjuvant treatment options for HER2-positive breast cancer

Hikmat Abdel-Razeq
Lina Marei
Section of Hematology and Medical Oncology, Department of Internal Medicine, King Hussein Cancer Center, Amman, Jordan

Abstract: Approximately one quarter of patients with breast cancer demonstrate amplification of the human epidermal receptor type 2 (HER2) gene, the expression of which is associated with a relatively poor prognosis independent of other clinical and pathologic variables. Trastuzumab, a humanized recombinant monoclonal antibody specifically directed against the HER2 receptor, has been shown to be biologically active and of considerable clinical utility in HER2-positive breast cancer patients. Neoadjuvant chemotherapy has been used in breast cancer to downstage the tumor and increase the opportunity for breast-conserving surgery. Preoperative chemotherapy can also serve as an in vivo testing of chemotherapy sensitivity. Additionally, a pathologic complete response is usually a surrogate marker of disease-free survival. Following the successful use of trastuzumab in the metastatic and adjuvant settings, many clinical trials have recently reported the successful use of anti-HER2 therapy in combination with different chemotherapy regimens in the neoadjuvant setting with a significantly higher pathologic complete response. With the recent introduction of new anti-HER2 drugs, interest has shifted toward dual HER2 blockade. Two such studies were recently reported, both showing a significant advantage of dual anti-HER2 therapy using lapatinib or pertuzumab in addition to trastuzumab and chemotherapy. However, several key questions need to be investigated further, such as the preferred combination chemotherapy and the optimal duration of trastuzumab in patients who achieve a pathologic complete response following preoperative chemotherapy with trastuzumab. These issues and others are discussed in this review.

Keywords: neoadjuvant, breast cancer, trastuzumab, pertuzumab, lapatinib

Introduction

Neoadjuvant therapy, also known as primary systemic treatment, was initially introduced for the treatment of inoperable locally advanced or inflammatory breast cancer. Increasingly, primary systemic treatment is now considered for women with large but operable disease. The rationale of this approach is to provide early chemotherapy that allows theoretical downstaging of the tumor, higher rates of breast-conserving surgeries, and in vivo testing of tumor response to the chosen chemotherapy.1–5 Despite the various definitions of pathologic complete response in the neoadjuvant trials, the correlation of pathologic complete response with improved disease-free survival and overall survival has already been demonstrated in several studies and is currently used as a surrogate marker for chemotherapy benefit in the neoadjuvant setting.6–8

Neoadjuvant chemotherapy has been compared with adjuvant chemotherapy using the same drug regimens in patients with operable breast cancer, with no difference in overall survival or disease-free survival. In the National Surgical Adjuvant Breast
and Bowel Project (NSABP) B18 trial, patients with clinical T1-3, N0-1 breast cancer were randomly assigned to neoadjuvant or adjuvant chemotherapy utilizing four cycles of adriamycin + cyclophosphamide. There was no statistically significant difference between neoadjuvant and adjuvant chemotherapy in nine-year overall survival. At 16 years of follow-up, the difference in overall survival between the two groups remained statistically insignificant (hazard ratio [HR] 0.99; 95% confidence interval [CI] 0.85–1.16).10

Similar conclusions were reached utilizing different chemotherapy regimens. The European Organisation for Research and Treatment of Cancer 10902 trial randomized patients with clinical T1c–T4b breast cancer to neoadjuvant or adjuvant chemotherapy with four cycles of fluorouracil + epirubicin + cyclophosphamide. At a median follow-up of 56 months, there was no significant difference between neoadjuvant and adjuvant chemotherapy in terms of four-year overall survival (82% versus 84%) or progression-free survival (65% versus 70%).11

Many neoadjuvant clinical trials have been reported utilizing different chemotherapeutic agents, the more recent of which have utilized taxanes (paclitaxel or docetaxel) and anthracyclines (adriamycin [doxorubicin] or epirubicin) in their regimens. The NSABP B27 trial utilized four cycles of adriamycin + cyclophosphamide with or without four cycles of docetaxel, with the surgery performed before or after the docetaxel. Compared with preoperative adriamycin + cyclophosphamide alone, preoperative adriamycin + cyclophosphamide followed by docetaxel increased the clinical complete response rate (40.1% versus 63.6%; P < 0.001), the overall clinical response rate (85.5% versus 90.7%; P < 0.001), the pathologic complete response rate (13.7% versus 26.1%; P < 0.001), and the proportion of patients with negative nodes (50.8% versus 58.2%; P < 0.001).12 Similar results were also achieved in the Aberdeen trial utilizing different docetaxel-based neoadjuvant chemotherapy.13

Approximately one quarter of patients with breast cancer demonstrate overamplification of the human epidermal receptor type 2 (HER2) gene, resulting in an overexpression of the HER2 receptor, a transmembrane tyrosine kinase receptor, the activation of which is known to result in increased activity of a variety of molecular pathways associated with tumor growth and progression.14 Extensive published data have demonstrated that patients whose cancers overexpress HER2 have a relatively poor prognosis independent of other clinical and pathologic variables, like tumor size and nodal status.15–17

Trastuzumab, a humanized recombinant monoclonal antibody specifically directed against the HER2 receptor, has been shown to be biologically active and of considerable clinical utility in HER2-positive breast cancer patients.18 Trastuzumab was approved by the US Food and Drug Administration in 1998 after a landmark Phase III trial in women with HER2-positive metastatic breast cancer showed dramatic improvement in overall response rates and overall survival with the addition of trastuzumab to standard first-line chemotherapy consisting of doxorubicin + cyclophosphamide or paclitaxel.19 Many Phase II trials have reported similar clinical benefit when this drug is combined with a number of other chemotherapeutic agents including docetaxel, vinorelbine, capetitabine, and gemcitabine, in both front-line and pretreated metastatic settings.20–25

So far, the results of five Phase III randomized trials exploring the benefit of adding trastuzumab to adjuvant chemotherapy for early HER2-positive breast cancer patients have been reported.26–31 All trials demonstrated significant improvement in disease-free survival. The HERA (Herceptin Adjuvant) trial26,27 and the joint analysis of two other studies, NSABP B31 and North Central Cancer Treatment Group N31,30 also showed an improved overall survival.

The encouraging data from published clinical trials resulted in enormous interest in incorporating trastuzumab into the neoadjuvant setting in women with HER2-positive breast cancer, hoping to improve the outcome of such patients. The present paper reviews the present clinical trials in this regard and outline the main results and their impact on clinical practice.

**First randomized trial**

The use of concurrent chemotherapy and trastuzumab in the preoperative setting has been investigated in several studies. In one of the initial trials, Buzdar et al from the MD Anderson Cancer Center randomized patients with HER2-positive, early-stage operable breast cancer to receive four cycles of paclitaxel every three weeks followed by four cycles of fluorouracil + epirubicin + cyclophosphamide with or without concomitant weekly trastuzumab. The addition of trastuzumab to neoadjuvant chemotherapy significantly increased the pathologic complete response rate from 26.3% in the chemotherapy arm alone to 65.2% in the trastuzumab arm (P = 0.016).32 The study was closed prematurely after recruiting only 42 patients, and a third, open-label, nonrandomized cohort (n = 22) was added to the study, and all were assigned to the trastuzumab arm. Among the 45 patients who received chemotherapy plus trastuzumab, the pathologic
complete response rate was 60% (95% CI 44.3–74.3). Both the
one-year, disease-free survival rate (100% versus 94.7% in
the chemotherapy plus trastuzumab and chemotherapy
alone arms, respectively) and the three-year, disease-free
survival rate (100% versus 85.3%, respectively) improved
with the addition of trastuzumab which was significant
\( P = 0.041 \) among the randomized arms.\(^3\) However, the
addition of trastuzumab to neoadjuvant therapy had a minimal
effect on the rate of breast-conserving therapy performed
(52.6% and 56.5% of patients in the chemotherapy alone and
chemotherapy with trastuzumab arms, respectively).

**Larger Phase III trials**
The use of trastuzumab was also assessed in larger clinical
trials in patients with newly diagnosed locally advanced
or inflammatory breast cancer. The NOAH (Neoadjuvant
Herceptin) trial was a large, international Phase III trial
designed to assess the efficacy and safety of sequential
doxorubicin + paclitaxel followed by paclitaxel, then cyclo-
phosphamide + methotrexate + 5-fluouracil with \( n = 117 \)
or without \( n = 118 \) concomitant trastuzumab, in patients
with newly diagnosed locally advanced breast cancer. A
third arm of patients \( n = 99 \) with HER2-negative disease
who received the same regimen but without trastuzumab
was also included. Patients with HER2-positive disease
who received neoadjuvant chemotherapy with concurrent
trastuzumab had a significantly improved overall response
rate \( (87\% \text{ versus } 74\% ; P = 0.009) \) and pathologic complete
response rate in breast tissue \( (43\% \text{ versus } 22\% ; P = 0.0007) \)
compared with those who received neoadjuvant chemother-
apy alone. A significant improvement in the pathologic
complete response rate was also observed in a subgroup
analysis of patients with inflammatory breast cancer who
received trastuzumab compared with those who did not \( (39\% \text{ versus } 20\% ; P = 0.002) \). At a median follow-up of 3.2 years,
the three-year, event-free survival improved significantly in
patients with HER2-positive disease who received chemother-
apy plus trastuzumab compared with those who received
chemotherapy alone \( (71\% \text{ versus } 56\% ; HR 0.59 ; P = 0.013) \).
For HER2-positive patients, the three-year overall survival
of trastuzumab arm as compared with chemotherapy alone
arm was 87% \( (95\% \text{ CI } 79–92) \) and 79% \( (95\% \text{ CI } 70–86) \),
respectively \( (P = 0.114) \).\(^3\)

The German Breast Group/Gynecologic Oncology Study
Group (GeparQuattro) trial was also designed to evaluate the
effect of trastuzumab on pathologic complete response rates
in a group of 1509 patients with either locally advanced (T3 or
T4), hormone receptor-negative or hormone receptor-positive
but lymph node-positive tumors. All patients were scheduled
to receive four cycles of epirubicin 90 mg/m\(^2\) and cyclo-
phosphamide 600 mg/m\(^2\) and were then randomly assigned
to three treatment arms; the first arm received four cycles of
docetaxel 100 mg/m\(^2\) (EC-D), the second arm received four
cycles of docetaxel 75 mg/m\(^2\) + capecitabine 1800 mg/m\(^2\)
(EC-DX) while the third arm received four cycles of doc-
etaxel 75 mg/m\(^2\) followed by four cycles of capecitabine
1800 mg/m\(^2\) on days 1–14 (EC-D-X). In each arm, patients
with HER2-positive disease received trastuzumab start-
ing from the initiation of the EC for 52 weeks. Patients
with HER2-negative tumors received chemotherapy only.
In total, 445 patients with HER2-positive tumors were
included. Pathologic complete response rate, defined as no
invasive or in situ residual tumors in the breast, was 31.7% for
patients who had received neoadjuvant trastuzumab plus
chemotherapy and 15.7% for patients who received chemother-
apy alone \( (P < 0.001) \). In the HER2-positive group, a
pathologic complete response was observed in 48 \( (32.9\%) \) of
146 patients treated with EC-D, 45 \( (31.3\%) \) of 144 patients
treated with EC-DX, and 47 \( (34.6\%) \) of 136 patients treated
with EC-D-X. The rate of breast-conserving surgery was
comparable among patients in the HER2-positive group
\( (63.1\%) \) and the HER2-negative reference group \( (64.7\%) \).\(^3\)
Results of these major trastuzumab-based neoadjuvant trials
are summarized in Table 1.

**Newer anti-HER2 drugs**
The HER family consists of four transmembrane receptors
that mediate a complex network of signaling pathways,\(^6\) and
HER1, HER2, and HER3 are all implicated in the develop-
ment and progression of cancer.\(^7\) While the role of the HER4
receptor in breast cancer is unclear, the HER3 receptor is
 gaining increasing interest in cancer research.\(^8\)

Ligand binding to the extracellular domain of the HER
receptor initiates a conformational rearrangement, exposing
the dimerization (receptor pairing) domain that forms
the core of the dimer interface with another HER receptor.
HER2 has no identified ligands and exists in an open confor-
mation that allows dimerization with other HER receptors.\(^9\)
HER2 and HER3 are highly complementary to each other,
and HER3 binds ligand yet lacks intrinsic kinase activity while
HER2 has intrinsic tyrosine kinase activity but no identified
ligand.\(^3\) HER2 dimerizes preferentially with HER3 to drive
downstream signaling.\(^40,41\)

Pertuzumab is the first of a new class of targeted anti-
cancer agents known as the HER2 dimerization inhibitors.\(^2\)
It is a humanized monoclonal antibody that binds to the
dimerization domain of HER2, which is an extracellular region essential for HER activation and signaling. The mechanism of action of pertuzumab, ie, inhibition of HER2 dimerization, is unique compared with that of other HER-targeted therapies. By blocking the pairing of the most potent signaling HER dimer, ie, HER2:HER3, pertuzumab affects key signaling pathways that mediate cell proliferation and survival in some cancers such as the breast. In vitro and in vivo studies have shown that pertuzumab works synergistically with trastuzumab to inhibit breast tumor cell survival.

Lapatinib is an orally active small molecule which reversibly inhibits both HER1 and HER2 tyrosine kinase domains. This concurrent inhibition in HER1-expressing and HER2-expressing tumors blocks the activating signaling cascades in the MAPK and PI3 K pathways, resulting in growth arrest and/or apoptosis, as shown in cell line and xenograft models. As a single agent, lapatinib has efficacy similar to that of lapatinib plus trastuzumab monotherapy in the first-line treatment of HER2-positive metastatic breast cancer, and was approved by the US Food and Drug Administration in 2006 based on a Phase III trial demonstrating improved progression-free survival with the combination of lapatinib and trastuzumab compared with trastuzumab alone in patients with trastuzumab-refractory disease. Because lapatinib is a small molecule that can penetrate the blood-brain barrier, it is now being extensively studied for the treatment and prevention of central nervous system metastases.

### Table 1 Summary of major trastuzumab-based neoadjuvant trials in breast cancer

<table>
<thead>
<tr>
<th>Trial</th>
<th>Phase</th>
<th>Treatment</th>
<th>Patients</th>
<th>Tumor size (T)</th>
<th>Node status (N)</th>
<th>pCR</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Buzdar et al</td>
<td>III and II</td>
<td>P → FEC + T</td>
<td>22</td>
<td>3</td>
<td>14</td>
<td>5</td>
<td>0</td>
</tr>
<tr>
<td>NOAH</td>
<td>III</td>
<td>AP → P + CMF + T</td>
<td>117</td>
<td>49 (42%)</td>
<td>32 (27%)</td>
<td>16 (14%)</td>
<td>50 (43%)</td>
</tr>
<tr>
<td>Gianni et al</td>
<td>III</td>
<td>A P + CMF</td>
<td>118</td>
<td>51 (43%)</td>
<td>31 (26%)</td>
<td>19 (16%)</td>
<td>53 (45%)</td>
</tr>
<tr>
<td>GeparQuattro</td>
<td>HER2-positive</td>
<td>EC → D with T</td>
<td>146</td>
<td>67 (15.1%)</td>
<td>245 (55.1%)</td>
<td>51 (11.4%)</td>
<td>37 (8.3%)</td>
</tr>
<tr>
<td>Untch et al</td>
<td>HER2-negative</td>
<td>Chemotherapy only</td>
<td>136</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Notes:** *pCR, no evidence of residual invasive cancer; both in breast and axilla; †pCR, pathologic complete response in breast tissue; ‡, defined as no invasive or in situ residual tumor in the breast; ‡‡Versus chemotherapy alone; ‡‡‡HER2-positive treated with trastuzumab versus HER2-negative treated with chemotherapy alone.

**Abbreviations:** P, paclitaxel; F, fluorouracil; E, epirubicin; C, cyclophosphamide; T, trastuzumab; D, docetaxel; X, capecitabine; A, adriamycin; NR, not reported; T4d, inflammatory breast cancer; pCR, pathologic complete response.
pathologic complete response. Although no significant cardiac toxicity was reported, patients in the lapatinib arm suffered more toxicity than those in the trastuzumab arm including an increased incidence of diarrhea, hepatotoxicity, neutropenia, and skin disorders. More patients discontinued treatment because of adverse events with combination therapy. This concept of dual anti-HER2 therapy is being tested in the adjuvant setting in the ALTTO trial which is about to conclude, having accrued its target of 8200 patients.48

The other major dual anti-HER-2 neoadjuvant trial is NeoSphere, which looked at a combined blockade using trastuzumab + pertuzumab versus trastuzumab alone. This study was unique in including an arm that did not receive any chemotherapy, just the dual blockade. In this study, which was also presented at the 33rd San Antonio Breast Cancer Symposium, women with operable, locally advanced, or inflammatory breast cancer were randomized to receive four cycles every three weeks of docetaxel + trastuzumab or docetaxel + trastuzumab + pertuzumab. The other two arms received docetaxel + pertuzumab or the doublet of the two monoclonal antibodies, trastuzumab + pertuzumab, without chemotherapy. After surgery, all patients received three cycles of fluorouracil + epirubicin + cyclophosphamide + trastuzumab every three weeks for one full year. The pathologic complete response rate was 45.8% for the combined regimen of two monoclonals compared with 29% for the trastuzumab arm (P = 0.014) and 24% for the pertuzumab arm (P = 0.003). The pathologic complete response in women who received the two monoclonals without chemotherapy was 16.8%, thus raising the question whether a subgroup of breast cancer patients can be treated with monoclonal agents and thus avoid chemotherapy. One patient developed congestive heart failure with trastuzumab and pertuzumab.49 Results of these dual anti-HER2 blockade neoadjuvant trials are summarized in Table 2.

### Significance of pathologic complete response

Pathologic complete response has been almost universally adopted in the neoadjuvant trials as a reliable endpoint and has been shown to correlate with both disease-free survival and overall survival in many of these trials.10,12,50 However, the precise definition among different trials varies; earlier trials referred to pathologic complete response as absent tumor histologically in both the breast and axilla. Later, it was regarded as absence of tumor cells in breast tissues only. In addition, some trials looked at both invasive and noninvasive (carcinoma in situ) components in the residual tumor following the neoadjuvant therapy.

Several trials have shown that the extent of residual breast cancer burden and lymph node metastases correlates with disease-free survival. In one trial, Hennessy et al reviewed response data for 925 patients treated in five prospective neoadjuvant trials, including 403 patients with cytologically confirmed axillary lymph node metastases. Eighty-nine patients (22%) achieved a pathologic complete response in the axillary lymph nodes following neoadjuvant therapy. The outcome for patients who achieved axillary lymph node pathologic complete response with neoadjuvant chemotherapy was compared with those having residual disease in the axillary lymph nodes. Median follow-up was 64 (range 15–178) months. The five-year overall survival and relapse-free survival rates were significantly better in patients with a pathologic complete response in the axillary lymph nodes (93% [95% CI 87.5–98.5] and 87% [95% CI 79.7–94.3] versus 72% [95% CI 66.5–77.5] and 60% [95% CI 54.1–65.9], respectively; P < 0.0001).51

Updated follow-up data from both the NSABP-B18 and B27 trials have shown similar trends.10 The TECHNO trial also addressed this issue after neoadjuvant chemotherapy and trastuzumab. In this trial, over 200 HER2-positive patients

### Table 2 Summary of pCR with dual anti-HER2 blockade in neoadjuvant breast cancer trials

<table>
<thead>
<tr>
<th>Trial</th>
<th>Chemotherapy regimens</th>
<th>Patients</th>
<th>pCR</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neo-ALTTO</td>
<td>Lapatinib + paclitaxel</td>
<td>154</td>
<td>24.7%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trastuzumab + paclitaxel</td>
<td>149</td>
<td>29.5%</td>
<td>0.0001*</td>
</tr>
<tr>
<td></td>
<td>Lapatinib + trastuzumab + paclitaxel</td>
<td>152</td>
<td>51.3%</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trastuzumab + docetaxel</td>
<td>107</td>
<td>29%</td>
<td>**</td>
</tr>
<tr>
<td></td>
<td>Pertuzumab + docetaxel</td>
<td>96</td>
<td>24%</td>
<td>0.03</td>
</tr>
<tr>
<td>NeoSphere</td>
<td>Trastuzumab + pertuzumab + docetaxel</td>
<td>107</td>
<td>45.8%</td>
<td>0.014</td>
</tr>
<tr>
<td></td>
<td>Trastuzumab + pertuzumab</td>
<td>107</td>
<td>16.8%</td>
<td>0.031</td>
</tr>
</tbody>
</table>

**Notes:** *P values as compared with trastuzumab + paclitaxel; **P values as compared with trastuzumab + docetaxel. Neo-ALTTO: lapatinib 1500 mg/day, if combined with trastuzumab 1000 mg/day, reduced to 750 mg/day with paclitaxel in 2008. Paclitaxel 80 mg/m²/week. Trastuzumab 4 mg/kg loading then 2 mg/kg/week. NeoSphere: pertuzumab 840 mg loading dose and 420 mg maintenance; trastuzumab 8 mg/kg loading dose and 6 mg/kg maintenance; docetaxel 75 mg/m² with escalation to 100 mg/m² if the starting dose was well tolerated.

**Abbreviation:** pCR, pathologic complete response.
received neoadjuvant epirubicin + cyclophosphamide for four cycles every three weeks followed by paclitaxel 175 mg/m² once every three weeks + trastuzumab 6 mg/kg every three weeks after a loading dose of 8 mg/kg. Chemotherapy was followed by surgery. Trastuzumab was continued after surgery until completion of 12 months of treatment. The three-year median follow-up data were recently presented and showed a three-year, disease-free survival of 88% compared with a rate of 73% among the patients who failed to achieve pathologic complete response ($P = 0.011$). Similarly, overall survival was also better (96%) compared with a rate of 86% ($P = 0.025$).\textsuperscript{52}

**Cardiac toxicity**

Cardiac toxicity was an unexpected finding during the clinical development of trastuzumab. Therefore, baseline cardiac evaluation or prospective monitoring were not mandated in early clinical trials in the metastatic setting. Also, patients with underlying cardiac disease were not excluded. In the adjuvant setting, trastuzumab was associated with a low but real risk of severe congestive heart failure or cardiac death, ranging from 0.6% in the HERA trial\textsuperscript{26,27} to 3.9% in NSABP-B31\textsuperscript{10} in patients who had prior anthracyclines. The majority of the observed trastuzumab-related cardiac events were asymptomatic decreases in left ventricular ejection fraction (L VEF), and both symptomatic and asymptomatic events were largely reversible.

In a meta-analysis including 10,955 patients treated in adjuvant trials, the risk of symptomatic, clinically significant (grade 3 to 4) heart failure following one year of trastuzumab versus chemotherapy not containing trastuzumab was 1.9% versus 0.3%, while the risk of an asymptomatic decrease in L VEF, and both symptomatic and asymptomatic events were largely reversible.\textsuperscript{53}

Simultaneous administration of trastuzumab + epirubicin in the MD Anderson Cancer Center study has raised the concern for cardiac toxicity. Among patients randomized to fluorouracil + epirubicin + cyclophosphamide and trastuzumab, the median L VEF decreased from 65% to 60% by the end of follow-up, but the L VEF range remained nearly constant. None of the 45 patients treated with chemotherapy and trastuzumab in the initial and the assigned cohort experienced clinical cardiac dysfunction, and there were no cardiac deaths in this study.\textsuperscript{32}

In the GeparQuattro Study, congestive heart failure and cardiac ischemia were reported in two patients each treated with chemotherapy alone and in one patient treated with chemotherapy and trastuzumab. A decrease in L VEF to 45% was reported in five patients and an L VEF decrease of more than 10% from baseline was reported in two patients treated with trastuzumab.\textsuperscript{32} Similar trends were also noted in the NOAH trial.\textsuperscript{34}

The risk of cardiac toxicity can be reduced by close cardiac monitoring during therapy and by avoiding treating patients with a baseline L VEF < 50%. Older patients with baseline L VEF 50%–55% and cardiac risk factors such as smoking, hypertension, body mass index > 25, and diabetes mellitus should be treated cautiously with close cardiac surveillance. Extending the window between the completion of anthracycline chemotherapy and initiation of trastuzumab, and administering trastuzumab with a nonanthracycline chemotherapy regimen may be a good option for high-risk patients with underlying cardiac disease or borderline L VEF. Biomarkers such as troponin and brain natriuretic peptide are being explored as potential early markers of cardiac injury, as is the prophylactic use of cardiac medications.\textsuperscript{54}

**Future directions**

A larger randomized Phase III clinical trial, ie, NSABP-B41, is currently ongoing to evaluate pathologic complete response rate with the administration of adriamycin + cyclophosphamide followed by weekly paclitaxel in combination with trastuzumab, lapatinib, or a combination of both trastuzumab and lapatinib, in the preoperative setting for patients with palpable and operable HER-2 positive breast cancer (NCT00486668).\textsuperscript{55}

There is growing interest in identifying biologic markers that would help tailoring treatment to individuals by recognizing reliable response predictors. Such markers may be related to cell proliferation, cell cycles, angiogenesis, or signal transduction. In the previously discussed NeoSphere study, tumor and blood specimens from >95% of patients have been collected and are being probed.\textsuperscript{49}

HER2-specific vaccines are an interesting new concept that have been evaluated in preclinical studies, with the hypothesis that generation of an anti-HER2 immune response may lead to slower tumor development at early stages. Different vaccine strategies are being tested.\textsuperscript{56}

Several other key questions need to be investigated further, such as the preferred chemotherapy for combination with trastuzumab (anthracycline versus nonanthracycline-based therapy) and the optimal duration of trastuzumab in patients who achieve pathologic complete response after preoperative chemotherapy with trastuzumab. Lastly, a randomized clinical trial comparing the benefit
of trastuzumab in combination with chemotherapy in the preoperative versus postoperative setting is also needed to determine the best strategy to administer trastuzumab-based chemotherapy.

**Conclusion**

Many good quality clinical studies suggest that trastuzumab should be incorporated in the preoperative treatment of women with HER2-positive disease, a fact that is already incorporated into the current National Comprehensive Cancer Network guidelines. As discussed in this paper, several key questions still need to be addressed, including the preferred combination chemotherapy and the optimal duration of trastuzumab in patients who achieve a complete pathologic response after preoperative chemotherapy.

**Acknowledgments**

The authors would like to thank Ms Haifa Al-Ahmad and Mrs Alice Haddadin for their help in preparing this manuscript.

**Disclosure**

The authors report no conflict of interest in this work.

**References**


40. Graus-Porta D, Beerli RR, Daly JM, Hynes NE. ErbB-2, the preferred partner of the ErbB-3 tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene. 2002;21:6253–6263.


